Managing dyslipidemia in the high-risk patient

The American Journal of Cardiology
Evan A Stein

Abstract

Lipid-lowering agents have been shown to reduce morbidity and mortality associated with coronary artery disease (CAD) in all patients. However, these agents are more cost-effective in high-risk patients whose absolute risk of CAD is greater than that of low-risk patients. Furthermore, from preliminary data, it appears that there is greater risk reduction in those subjects achieving lower low-density lipoprotein cholesterol (LDL-C) levels (ie, lower is better). The identification and aggressive treatment of these patients should therefore be a high priority for clinicians. Guidelines from medical organizations, such as the Adult Treatment Panel (ATP) III of the US National Cholesterol Education Program (NCEP), emphasize that patients with CAD, diabetes, or global risk of CAD >20% over 10 years and LDL-C levels >130 mg/dL should receive drug therapy with a goal of reducing LDL-C levels to <100 mg/dL. The recent results of the United Kingdom's Heart Protection Study (HPS) strongly suggest that even those with CAD or who are at high risk and LDL-C levels >100 mg/dL would benefit from drug therapy. Although optimal LDL-C levels have been set at <100 mg/dL for high-risk patients, recent studies show only about 20% of such patients me...Continue Reading

References

Nov 1, 1972·Journal of Chronic Diseases·T Gordon, W B Kannel
May 1, 1966·The American Journal of Physiology·L Lack, I M Weiner
Jul 1, 1997·The American Journal of Cardiology·W C Roberts
Oct 20, 1998·Archives of Internal Medicine·T A JacobsonC M Ballantyne
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jan 23, 1999·The American Journal of Cardiology·J R Guyton, D M Capuzzi
Aug 12, 1999·The New England Journal of Medicine·R H Knopp
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Aug 29, 2001·The American Journal of Cardiology·A G OlssonA Raza
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers

❮ Previous
Next ❯

Citations

Nov 9, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·V SchettlerUNKNOWN Participants of the Göttingen Consensus Conferences
Feb 11, 2010·The Journal of Veterinary Medical Science·Hisashi MizutaniHisashi Hirose
Dec 14, 2004·International Journal of Clinical Practice·G De Angelis
Apr 14, 2012·The Mount Sinai Journal of Medicine, New York·Kieron B L Lim, Thomas D Schiano
Apr 25, 2006·Metabolism: Clinical and Experimental·Carlo M BarbagalloMaurizio R Averna
Sep 30, 2009·Current Medical Research and Opinion·Leiv OseValerie Arneson
Apr 2, 2005·British Journal of Clinical Pharmacology·E Van GanseG de Pouvourville
Aug 30, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Maria Alice V WillrichRosario D C Hirata
Feb 18, 2004·The Annals of Pharmacotherapy·A Juhani KahriPertti J Pentikäinen
Sep 15, 2005·Heart and Vessels·San-Chiang WuChun-Peng Liu
Dec 17, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Lorenzo NestiAndrea Natali
Aug 29, 2003·Thérapie·Pascal Bousquet, Jean-Louis Gayet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.